Logo

LMNX

Defiance Daily Target 2X Long LMND ETF

LMNX

Defiance Daily Target 2X Long LMND ETF • NASDAQ
$37.56 ▲ 1.19% (+0.44)
Market Cap $2.62 M
52w High $44.17
52w Low $15.95
Dividend Yield 0%
P/E 0
Volume 13.11K
Outstanding Shares 69.83K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2021 $110.688M ▼ $53.002M ▼ $9.082M ▲ 8.205% ▲ $0.2 ▲ $21.03M ▲
Q4-2020 $111.393M ▲ $53.944M ▲ $239K ▼ 0.215% ▼ $0.005 ▼ $-9.568M ▼
Q3-2020 $106.06M ▼ $51.855M ▲ $1.767M ▼ 1.666% ▼ $0.039 ▼ $18.759M ▼
Q2-2020 $109.519M ▲ $50.905M ▲ $12.51M ▲ 11.423% ▲ $0.28 ▲ $26.143M ▲
Q1-2020 $90.424M $48.705M $654K 0.723% $0.015 $8.462M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2021 $271.56M ▼ $819.031M ▲ $330.984M ▲ $488.047M ▼
Q4-2020 $309.407M ▲ $770.118M ▼ $307.752M ▲ $517.711M ▲
Q3-2020 $308.454M ▲ $810.945M ▲ $294.848M ▲ $516.097M ▲
Q2-2020 $291.665M ▲ $784.177M ▲ $279.916M ▲ $504.261M ▲
Q1-2020 $43.077M $531.923M $69.417M $462.506M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2021 $9.082M ▲ $-21.562M ▼ $-13.448M ▼ $-3.289M ▼ $-37.847M ▼ $-35.01M ▼
Q4-2020 $239K ▼ $10.927M ▼ $-6.296M ▼ $-3.127M ▼ $953K ▼ $4.631M ▼
Q3-2020 $1.767M ▼ $14.944M ▼ $-3.515M ▲ $5.755M ▼ $16.789M ▼ $11.429M ▼
Q2-2020 $12.51M ▲ $31.276M ▲ $-4.176M ▼ $221.562M ▲ $248.588M ▲ $27.1M ▲
Q1-2020 $654K $-7.216M $-3.901M $-5.024M $-16.096M $-11.139M

Revenue by Products

Product Q4-2013Q1-2014Q2-2014Q3-2014
Assays and Related Products
Assays and Related Products
 $20.00M ▲$20.00M ▲$20.00M ▲$20.00M ▲
Technology and Strategic Partnerships
Technology and Strategic Partnerships
 $40.00M ▲$30.00M ▼$30.00M ▲$30.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Luminex showed a healthy ability to make money on each test and instrument it sold, with solid gross margins typical of specialized diagnostics. After covering research, sales, and administrative costs, it still generated a modest but clearly positive operating profit. Bottom-line earnings were positive as well, indicating the core business was profitable rather than dependent on one-off items. Overall, the income statement reflects a steady, profitable niche player rather than a high-growth, high-loss story.

Balance Sheet

Balance Sheet The balance sheet looks conservative and resilient. The company held a sizeable cushion of cash relative to its overall asset base, which provides flexibility for investment and protection in downturns. Debt was present but not overwhelming, and equity funded a substantial portion of the business, suggesting no aggressive leverage. In plain terms, Luminex appeared financially sturdy, with room to navigate industry cycles and integration under DiaSorin.

Cash Flow

Cash Flow Luminex generated cash from its day-to-day operations, and this cash comfortably covered its relatively modest investment needs. After spending on equipment and related capital needs, it still produced positive free cash flow, which is a good signal of underlying economic strength. The business model looks more “asset-light,” relying more on technology, instruments, and consumables than on heavy factories, which typically supports consistent cash generation if demand remains stable. Overall, cash flows back up the story of a financially sound, self-funding business.

Competitive Edge

Competitive Edge Competitively, Luminex sits in a strong niche built around its multiplexing platforms, especially xMAP, which many labs and partners have integrated deeply into their workflows. Its installed base of instruments, broad menu of assays through partners, and long-standing patent estate create meaningful switching costs and barriers for rivals. At the same time, it faces capable competitors in molecular and syndromic testing, so maintaining relevance depends on menu breadth, ease of use, and cost per test. Being part of DiaSorin strengthens its commercial reach and portfolio breadth, but also means its role will be shaped by broader group strategy and integration success.

Innovation and R&D

Innovation and R&D Innovation is the heart of Luminex’s story. Its bead-based xMAP technology, newer INTELLIFLEX platform, and molecular systems like ARIES and Verigene give it a differentiated position in running many tests from small samples. The open-architecture design encourages custom assay development and a wide partner ecosystem, which effectively extends its R&D reach beyond its own labs. Looking forward, the most important innovation levers are next-generation multiplex platforms, new high-value clinical panels (especially in infectious disease and oncology), and deeper integration of its technologies into DiaSorin’s broader diagnostic systems.

Summary

Overall, Luminex appears as a profitable, cash-generative diagnostics and life sciences tools company with a defensible niche in multiplex testing. Its financial profile—solid margins, a conservative balance sheet, and positive free cash flow—supports ongoing investment in technology and assay development. The main strengths lie in its proprietary platforms, large installed base, and partner ecosystem, now backed by DiaSorin’s global distribution. Key uncertainties center on how effectively DiaSorin continues to invest in and integrate Luminex’s technologies, how well it competes in a crowded molecular diagnostics landscape, and whether it can keep expanding its test menu in the most attractive clinical and research areas.

NEWS

October 16, 2025 · 8:30 AM UTC

Defiance Launches LMNX: The First 2X Long ETF for Lemonade, Inc.

Read more